title: High serum adiponectin predicts incident fractures in elderly men: Osteoporotic fractures in men (MrOS) Sweden.
abstract: Adipocytes and osteoblasts share a common progenitor, and there is, therefore, potential for both autocrine and endocrine effects of adiponectin on skeletal metabolism. The aim of the present study was to determine whether high serum adiponectin was associated with an increased risk of fracture in elderly men. We studied the relationship between serum adiponectin and the risk of fracture in 999 elderly men drawn from the general population and recruited to the Osteoporotic Fractures in Men (MrOS) study in Gothenburg, Sweden. Baseline data included general health questionnaires, lifestyle questionnaires, body mass index (BMI), bone mineral density (BMD), serum adiponectin, osteocalcin, and leptin. Men were followed for up to 7.4 years (average, 5.2 years). Poisson regression was used to investigate the relationship between serum adiponectin, other risk variables and the time-to-event hazard function of fracture. Median levels of serum adiponectin at baseline were 10.4 µg/mL (interquartile range, 7.7-14.3). During follow-up, 150 men sustained one or more fractures. The risk of fracture increased in parallel with increasing serum adiponectin (hazard ratio [HR]/SD, 1.46; 95% confidence interval [CI], 1.23-1.72) and persisted after multivariate-adjusted analysis (HR/SD, 1.30; 95% CI, 1.09-1.55). Serum adiponectin shows graded stepwise association with a significant excess risk of fracture in elderly men that was independent of several other risk factors for fracture. Its measurement holds promise as a risk factor for fracture in men.
authors.affiliation: Centre for Bone and Arthritis Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. helena.johansson@mbox319.swipnet.se
authors.forename: Helena
authors.initials: H
authors.lastname: Johansson
authors.forename: Anders
authors.initials: A
authors.lastname: Odén
authors.forename: Ulf H
authors.initials: UH
authors.lastname: Lerner
authors.forename: Hans
authors.initials: H
authors.lastname: Jutberger
authors.forename: Mattias
authors.initials: M
authors.lastname: Lorentzon
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Barrett-Connor
authors.forename: Magnus K
authors.initials: MK
authors.lastname: Karlsson
authors.forename: Osten
authors.initials: O
authors.lastname: Ljunggren
authors.forename: Ulf
authors.initials: U
authors.lastname: Smith
authors.forename: Eugene
authors.initials: E
authors.lastname: McCloskey
authors.forename: John A
authors.initials: JA
authors.lastname: Kanis
authors.forename: Claes
authors.initials: C
authors.lastname: Ohlsson
authors.forename: Dan
authors.initials: D
authors.lastname: Mellström
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000368:Aged; D000369:Aged, 80 and over; D016001:Confidence Intervals; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D016014:Linear Models; D008297:Male; D015999:Multivariate Analysis; D058866:Osteoporotic Fractures / Q000097:blood* / Q000453:epidemiology*; D016012:Poisson Distribution; D016016:Proportional Hazards Models; D013548:Sweden / Q000453:epidemiology
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin